<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background: A Japanese postmarketing survey of panitumumab revealed that panitumumab-associated <z:hpo ids='HP_0006530'>interstitial lung disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ILD</z:e>) occurred in approximately 1% (19/1767) of patients, causing <z:hpo ids='HP_0011420'>death</z:hpo> in 36.8% of these cases </plain></SENT>
<SENT sid="1" pm="."><plain>Case Report: We report the case of a 60-year-old Japanese man who developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ILD</z:e> associated with panitumumab therapy (third-line therapy) for metastatic sigmoid <z:hpo ids='HP_0003003'>colon cancer</z:hpo> involving the liver, lymph nodes, and lungs </plain></SENT>
<SENT sid="2" pm="."><plain>2 months after the initiation of panitumumab therapy, he developed a progressive nonproductive cough, <z:hpo ids='HP_0002094'>dyspnea</z:hpo>, and a <z:hpo ids='HP_0001945'>fever</z:hpo>, and was diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ILD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Intravenous pulse <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> treatment led to quick recovery </plain></SENT>
<SENT sid="4" pm="."><plain>The patient had some risk factors for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ILD</z:e> associated with epidermal growth factor receptor (EGFR)-<z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Conclusion: Further studies are required to elucidate the association between anti-EGFR antibodies and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ILD</z:e> </plain></SENT>
</text></document>